Given that Rb is rarely lost in ESCC, while Fbxo4 loss or cyclin D1 amplification occurs at a high frequency, it is important to fill this knowledge gap in order to develop therapies for ESCC that may also be efficient for other tumors with dysregulation of this signaling pathway. Here, FBXO4 is linked to esophageal squamous cell carcinoma.